Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 2/20 | 0.43 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22795216 | 1.00 | DRD2 (0.54) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL22795471 | 1.00 | DRD2 (0.54) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL2603277 | 0.91 | DRD2 (0.63) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL21323287 | 0.91 | DRD2 (0.63) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL17658922 | 0.91 | DRD2 (0.63) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL2603307 | 0.86 | DRD2 (0.58) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL20322517 | 0.83 | DRD2 (0.55) | DRD2DRD3PARP1PARP2 | |
| SCHEMBL19459098 | 0.81 | DRD2 (0.53) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL19459097 | 0.81 | DRD2 (0.53) | DRD2DRD3PARP1PARP2DRD1 | |
| SCHEMBL19459176 | 0.81 | DRD2 (0.53) | DRD2DRD3PARP1PARP2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | DRD2 4779/4885DRD3 4596/4885PARP1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.